Kiminori Fujimoto

Kurume University

Papers

1

Total Citations

2

H-Index

1

About

Kiminori Fujimoto is a leading authority in thoracic oncology, with a specialized focus on lung cancers, malignant pleural mesotheliomas, and thymic tumors. His major contributions lie in the development of evidence-based medical practice guidelines, particularly for thymic epithelial tumors, where he has helped shape diagnostic and therapeutic standards in Japan. As a key contributor to the Japan Lung Cancer Society’s 2024 guidelines, Fujimoto’s work synthesizes complex clinical evidence into actionable recommendations, directly influencing patient care and clinical decision-making. His most cited paper, summarizing recommendations for thymic epithelial tumors, has garnered 2 citations, reflecting its foundational role in guiding practitioners. Beyond guideline development, Fujimoto’s research integrates radiology, pathology, and oncology, advancing the multidisciplinary management of thoracic malignancies. His achievements include co-authoring national consensus documents that serve as benchmarks for quality care, ensuring that Japanese clinical practice aligns with global evidence. For students and researchers, Fujimoto exemplifies how rigorous evidence synthesis can translate into practical tools that improve outcomes in rare and complex thoracic cancers.

Research Focus

Key Achievements

1
H-Index
1
Papers
2
Total Citations
2
Avg Citations/Paper
🏆 Most Cited Paper
Medical Practice Guidelines for Lung Cancers including malignant pleural mesotheliomas and thymic tumors according to evidence-based medicine. 2024. Edited by the Japan Lung Cancer Society. Chapter 3 Guidelines for thymic epithelial tumors – Summary of recommendations
2 citations · 2025
📈 Most Prolific Year: 2025 (1 Papers)
🤝 Key Collaborators: 17
🏛 Institutions: Kurume University

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago